Pharmacoeconomic analysis of the use of ibrutinib in therapy of the first line of a chronic lymphocytic leukaemia for patients with 17p deletion

Качественная клиническая практика

M. A. Proskurin¹  I. A. Vilum²  A. S. Kolbin³  Yu. E. Balykina⁴ 

[1] National Medical and Surgical Center of the N.I. Pirogov;Saint Petersburg State University, Saint Petersburg, Russia;First Pavlov State Medical University of Saint Petersburg, Saint Petersburg, Russia;First Pavlov State Medical University of St. Peterburg;

关键词: chronic lymphocytic leukemia;    ibrutinib;    pharmacoeconomics;    фармакоэкономика;    ибрутиниб;    хронический лимфолейкоз;   

DOI  :  

来源: DOAJ

【 摘 要 】

We have performed the first-ever comparative pharmacoeconomic analysis in a Russian context of ibrutinib in the first line of therapy of chronic lymphocytic leukemia at patients with a 17p deletion. Research was conducted from a position of the state health system by means of mathematical modeling. It was considered direct and indirect costs. Markov modeling and the sensitivity analysis were used. It was as a result shown that application of Imbruvica® in therapy of chronic lymphocytic leukemia at patients with a 17p deletion is an economically advantageous medical technology from the point of view of a ratio of cost and efficiency in comparing with strategy of an ofatumumab. It was as a result shown that application of Imbruvica® in therapy of chronic lymphocytic leukemia at patients with a 17p deletion is economically expedient medical technology from the point of view of a ratio of cost and efficiency when comparing with strategy of an ofatumumab. Also, this strategy was characterized by high clinical effectiveness and a comparable profile of safety among other medical technologies. As for the budget impact analysis, comparing with strategy of an ofatumumab widespread use of ibrutinib would allow saving up to an additional 80.5 millions rub per 1 000 patients with chronic lymphocytic leukemia, thus the saved means allow to treat with this strategy in addition 16 patients.

【 授权许可】

Unknown